For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Renal biomarkers help diagnose or identify the patients at risk of developing kidney diseases, by measuring their blood or urine levels. They are commonly released in acute or chronic kidney injuries, which are characterized by the rapid or gradual loss of kidney function resulting into serous clinical implications.
LPI (LP Information)' newest research report, the "Renal Biomarkers Industry Forecast" looks at past sales and reviews total world Renal Biomarkers sales in 2022, providing a comprehensive analysis by region and market sector of projected Renal Biomarkers sales for 2023 through 2029. With Renal Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Renal Biomarkers industry.
This Insight Report provides a comprehensive analysis of the global Renal Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Renal Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Renal Biomarkers market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renal Biomarkers and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renal Biomarkers.
The global Renal Biomarkers market size is projected to grow from US$ 1143.2 million in 2022 to US$ 1617.5 million in 2029; it is expected to grow at a CAGR of 5.1% from 2023 to 2029.
The major factors fuelling the global renal biomarkers market are increased incidence of kidney diseases, large geriatric population and increasing prevalence of multiple co-morbidities.
This report presents a comprehensive overview, market shares, and growth opportunities of Renal Biomarkers market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Enzyme Linked Immunosorbent Assay (ELISA)
- Enzymatic Assay
- Turbidimetric Immunoassay
- Others
Segmentation by application
- Diagnosis and Disease Progression Monitoring
- Research
- Others
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Abbott Diagnostics
- F. Hoffmann-La Roche
- Beckman Coulter
- Siemens Healthcare Diagnostics
- Thermo Fisher Scientific
- Astute Medical
- BioMerieux SA
- Randox Laboratories